Editors

Medactie

Write_alt-128.png

Medactie Editors bring a long experience of writing, editing and publishing in scientific journals. Medactie editors include English cancer researcher Dr. JP Bayley and the American neuroscientist Dr. Curtis Barrett

JP_Bayley.JPGDr. Bayley has worked on the genetics of cancer at Leiden University Medical Center for almost 20 years. A biochemist by training (University of Keele, UK), Dr. Bayley carried out his PhD work in the field of immunology and genetics at Leiden University Medical Center. Dr. Bayley developed the LOVD TCA Cycle gene mutation databases, the leading online mutation resource for TCA tumor suppressor genes, and has led many (national and international) studies in the field of hereditary cancer. Dr. Bayley has authored and co-authored over 50 biomedical manuscripts. As an active scientific editor for the last ten years, Dr. Bayley has edited a wide range of documents including manuscripts, grant proposals, pre-proposals and manuals

Important recent publications

  1. Hoekstra AS, et  al. Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. Oncotarget. 2017 Feb 28;8(9):14525-14536.
  2. Hoekstra AS, et  al. Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers. Hum Mol Genet. 2016 Sep 1;25(17):3715-3728.
  3. Hoekstra AS, et al. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget. 2015 Nov 17;6(36):38777-88.
  4. Bayley JP, et al. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet. 2014 Oct 10;15:111.
  5. Cerecer-Gil NY, et al. Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma. Clin Cancer Res. 2010 Aug 15;16(16):4148-54.
  6. Bayley JP, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010 Apr;11(4):366-72.
  7. Bayley JP, et al. Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma. PLoS One. 2009 Nov 24;4(11):e7987.
  8. Cervera AM, et al. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer. 2009 Oct 22;8:89.
  9. Hao HX, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009 Aug 28;325(5944):1139-42.
  10. van Nederveen FH, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009 Aug;10(8):764-71.


CFB_photo.jpg

Dr. Barrett received his PhD in 2001 from the program in Cellular and Molecular Physiology at the University of Massachusetts Medical Center. Following his postdoctoral training at Stanford University, he re-located with his family to the Netherlands to continue scientific research, focusing on the neurobiology of migraine. Dr. Barrett has authored several invited reviews and has authored 20 scientific and biomedical manuscripts. In his role as an editor, Dr. Barrett has edited hundreds of manuscripts, many of which have been published in high-impact, internationally respected journals. In addition, Dr. Barrett is available for lecturing and teaching courses and workshops on a variety of topics, including how to prepare scientific posters, how to use Endnote, PowerPoint and Excel to their full potential, the essentials of writing manuscripts and grant proposals, and other topics as needed

Ma H, Groth RD, Wheeler DG, Barrett CF, and RW Tsien (2011) Excitation-transcription coupling in sympathetic neurons and the molecular mechanism of its initiation. Neurosci. Rev. 70(1):2–8.

Gosso MF*, Barrett CF*, van den Maagdenberg AMJM, and MD Ferrari (2010) Pain-related mutations in the human genome. In: Pain 2010–An Updated Review: Refresher Course Syllabus. J Mogil, Ed. IASP Press. pp. 239–253. *, equal contribution

Barrett CF, van den Maagdenberg AMJM, Frants RR, and MD Ferrari (2008) Familial hemiplegic migraine. Advances in Genetics. 63:57–83.

Piedras-Rentería ES, Barrett CF, Cao Y-C, and RW Tsien (2007) Calcium channels, calcium signaling and channelopathies. In: Calcium: A Matter of Life or Death. J Krebs and M Michalak, Eds. Elsevier Press. pp. 127–166.

Tsien RW, and Barrett CF (2004) A brief history of calcium channel discovery. In: Voltage-Gated Calcium Channels. GW Zamponi, Ed. Plenum Press. pp. 27–47.

van den Maagdenberg AMJM, Pizzorusso T, Kaja S, Terpolilli N, Shapovalova M, Hoebeek FE, Barrett CF, Gherardini L, van de Ven RCG, Todorov B, Broos LAM, Tottene A, Gao Z, Fodor M, de Zeeuw CI, Frants RR, Plesnila N, Plomp JJ, Pietrobon D, and MD Ferrari. (2009) High CSD susceptibility and migraine-associated symptoms in CaV2.1 S218L mice. Annals of Neurol. 67(1):85–98.

Wheeler DG, Barrett CF, Groth RD, Safa P, and RW Tsien (2008) CaMKII locally encodes L-type channel activity to signal to nuclear CREB in excitation–transcription coupling. J. of Cell Biol. 183(5):849–863.

Watase K, Barrett CF, Miyazaki T, Sun Y, Kasai S, Watanabe M, Mizusawa H, Tsien RW, and HY Zoghbi (2008) Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc. Natl. Acad. Sci. USA. 105(33):11987–11992.

Barrett CF, and RW Tsien (2008) The Timothy syndrome mutation differentially affects voltage- and calcium-dependent inactivation of CaV1.2 L-type calcium channels. Proc. Nat. Acad. Sci. USA. 105(6):2157–2162.

Green EM, Barrett CF, Bultynck G, Shamah, SM, and RE Dolmetsch (2007) The tumor suppressor eIF3e mediates calcium-dependent internalization of the L-type calcium channel Ca(V)1.2. Neuron. 55(4):615–632. [Comment in: Varela D, and GW Zamponi (2007) Use ’em and lose ’em—activity-induced removal of calcium channels from the plasma membrane. Neuron. 55(4):539–541]

Wheeler DG*, Barrett CF*, and RW Tsien (2006) L-type calcium channel ligands block nicotine-induced signaling to CREB by inhibiting nicotinic receptors. Neuropharmacology. 51(1):27–36. *, equal contribution

Barrett CF, Cao Y-C, and RW Tsien (2005) Gating deficiency in a familial hemiplegic migraine type 1 mutant P/Q-type calcium channel. J. Biol. Chem. 280(5):24064–24071.

Liu L, Gonzalez PK, Barrett CF, and AR Rittenhouse (2003) The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents. Neuropharmacology. 45(2):281–292.

Barrett CF, Liu L, and AR Rittenhouse (2001) Arachidonic acid reversibly enhances N-type calcium current at an extracellular site. Am. J. Physiol. – Cell Physiol. 280(5):C1306–C1318.

Liu L, Barrett CF, and AR Rittenhouse (2001) Arachidonic acid both inhibits and enhances whole-cell calcium currents in rat sympathetic neurons. Am. J. Physiol. – Cell Physiol. 280(5):C1293–C1305.

Barrett CF, and AR Rittenhouse (2000) Modulation of N-type calcium channel activity by G-proteins and protein kinase C. J. Gen. Physiol. 115(3):277–286. [Comment in: Bean, B.P. (2000) Modulating modulation. J. Gen. Physiol. 115(3):273–275]